Michael J. Rybak
Impact in
- Clinical Biochemistry top 0.01%
- Bacterial Identification and Susceptibility Testing
- Infectious Diseases top 0.01%
- Antimicrobial Resistance in Staphylococcus
Papers in
-
- Antimicrobial Resistance in Staphylococcus 278
- Pharmacology 175
- Antibiotics Pharmacokinetics and Efficacy 170
- Co-authors
- Donald P. Levine (31 shared papers)Arnold S. Bayer (12 shared papers)Catherine Liu (6 shared papers)Glenn W. Kaatz (43 shared papers)Sara E. Cosgrove (6 shared papers)Barbara E. Murray (7 shared papers)David A. Talan (3 shared papers)Henry F. Chambers (2 shared papers)
- Journals
- Antimicrobial Agents and Chemotherapy (150 papers)Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (50 papers)Open Forum Infectious Diseases (32 papers)Journal of Antimicrobial Chemotherapy (26 papers)Infectious Diseases and Therapy (22 papers)
- Partner nations
- United StatesColombiaSpain
In The Last Decade
Michael J. Rybak
420 papers receiving 26.8k citations
Michael J. Rybak's Hit Papers
Peers
Comparison fields: 5 of 157
- Clinical Biochemistry 6.3k
- Infectious Diseases 14.8k
- Applied Microbiology and Biotechnology 1.5k
- Molecular Medicine 3.9k
- Pharmacology 6.9k
Countries citing papers authored by Michael J. Rybak
This map shows the geographic impact of Michael J. Rybak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Rybak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Rybak more than expected).
Fields of papers citing papers by Michael J. Rybak
This network shows the impact of papers produced by Michael J. Rybak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Rybak. The network helps show where Michael J. Rybak may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael J. Rybak, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 427 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children Hit paper breakdown → | 2011 | 3111 |
| 2 | Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications Hit paper breakdown → | 2015 | 1969 |
| 3 | Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Hit paper breakdown → | 2008 | 1404 |
| 4 | Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children: Executive Summary Hit paper breakdown → | 2011 | 1200 |
| 5 | Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists Hit paper breakdown → | 2020 | 741 |
| 6 | Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists Hit paper breakdown → | 2009 | 617 |
| 7 | The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin Hit paper breakdown → | 2005 | 600 |
| 8 | 2003 | 487 | |
| 9 | 2011 | 356 | |
| 10 | 2009 | 320 | |
| 11 | 1999 | 312 | |
| 12 | 2000 | 306 | |
| 13 | 2020 | 302 | |
| 14 | 1990 | 277 | |
| 15 | 2004 | 245 | |
| 16 | 2017 | 187 | |
| 17 | 2008 | 183 | |
| 18 | 2018 | 162 | |
| 19 | 2001 | 160 | |
| 20 | 2015 | 158 |
About Michael J. Rybak
Michael J. Rybak is a scholar working on Infectious Diseases, Pharmacology, Clinical Biochemistry, Molecular Medicine and Epidemiology, having authored 427 papers that have together received 27.6k indexed citations. Recurring topics across this work include Antimicrobial Resistance in Staphylococcus (278 papers), Antibiotics Pharmacokinetics and Efficacy (170 papers), Bacterial Identification and Susceptibility Testing (118 papers), Antibiotic Resistance in Bacteria (106 papers), Infective Endocarditis Diagnosis and Management (47 papers), Pneumonia and Respiratory Infections (38 papers), Antibiotic Use and Resistance (28 papers) and Streptococcal Infections and Treatments (27 papers). The work is most often cited by research in Clinical Biochemistry (6.3k citations), Infectious Diseases (14.8k citations), Applied Microbiology and Biotechnology (1.5k citations), Molecular Medicine (3.9k citations) and Pharmacology (6.9k citations). Michael J. Rybak has collaborated with scholars based in United States, Colombia and Spain. Frequent co-authors include Donald P. Levine, Arnold S. Bayer, Catherine Liu, Glenn W. Kaatz, Sara E. Cosgrove, Barbara E. Murray, David A. Talan, Henry F. Chambers, Adolf W. Karchmer and Scott K. Fridkin. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, Open Forum Infectious Diseases, Journal of Antimicrobial Chemotherapy and Infectious Diseases and Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.